Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “buy” rating reissued by equities researchers at Credit Suisse Group in a research note issued on Sunday. They presently have a $50.00 price objective on the biotechnology company’s stock. Credit Suisse Group’s price objective would indicate a potential downside of 20.46% from the company’s current price.
Several other equities analysts have also commented on the company. BidaskClub raised Ascendis Pharma A/S from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 25th. Bank of America lowered their target price on Ascendis Pharma A/S from $46.00 to $43.00 and set a “buy” rating for the company in a report on Friday, November 17th. JPMorgan Chase & Co. set a $50.00 target price on Ascendis Pharma A/S and gave the company a “buy” rating in a report on Wednesday, January 3rd. Zacks Investment Research lowered Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a report on Wednesday, December 13th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $52.67.
Ascendis Pharma A/S (NASDAQ:ASND) opened at $62.86 on Friday. The company has a market capitalization of $2,231.78, a P/E ratio of -17.27 and a beta of 1.02. Ascendis Pharma A/S has a fifty-two week low of $21.95 and a fifty-two week high of $63.69.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.